Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse

Item

http://www.wikidata.org/entity/Q36862529

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Myeloablative chemotherapy for ...... tial benefit in second relapse

@en

type

Item

label

Myeloablative chemotherapy for ...... tial benefit in second relapse

@en

prefLabel

Myeloablative chemotherapy for ...... tial benefit in second relapse

@en

P1476

Myeloablative chemotherapy for ...... tial benefit in second relapse

@en

P2093

Deborah Anderson

http://www.w3.org/2001/XMLSchema#string

Debra Lillington

http://www.w3.org/2001/XMLSchema#string

Janet Matthews

http://www.w3.org/2001/XMLSchema#string

John G Gribben

http://www.w3.org/2001/XMLSchema#string

Silvia Montoto

http://www.w3.org/2001/XMLSchema#string

T Andrew Lister

http://www.w3.org/2001/XMLSchema#string

P2860

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.

Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Stu

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

P304

620-625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2012.069583

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paul Greaves

P577

2012-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233396362

http://www.w3.org/2001/XMLSchema#string

P698

23144201

http://www.w3.org/2001/XMLSchema#string

P932

3659995

http://www.w3.org/2001/XMLSchema#string